Scott Kopetz, MD, PhD, FACP, on the BREAKWATER Study in BRAF V600–Mutant Metastatic Colorectal Cancer

January 27, 2025 By The ASCO Post Staff

The open-label, global, randomized phase III BREAKWATER study was an  analysis of first-line encorafenib plus cetuximab plus chemotherapy in patients with BRAF V600E–mutant metastatic colorectal cancer. Here, Scott Kopetz, MD, PhD, FACP, of The University of Texas MD Anderson Cancer Center, reports the primary analysis of objective response rate and the first interim analysis of overall survival (Abstract 16).

Related Content